VRX - Valeant Pharmaceuticals International, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
22.70
-0.27 (-1.20%)
At close: 3:59PM EST

22.70 -0.00 (-0.02%)
After hours: 4:01PM EST

Stock chart is not supported by your current browser
Previous Close23.84
Open23.01
Bid22.70 x 7400
Ask22.71 x 3000
Day's Range22.32 - 23.10
52 Week Range8.31 - 24.43
Volume11,163,298
Avg. Volume18,601,245
Market Cap7.907B
Beta-0.78
PE Ratio (TTM)5.79
EPS (TTM)3.92
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2010-11-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • InvestorPlace4 hours ago

    Valeant Pharmaceuticals Intl Inc Stock Rides High as More Good News Awaits

    Showering its investors with good news, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is trading close to its yearly highs. Since early November, VRX stock has more than doubled, and for good reason. The company extended the maturities of its upcoming debt obligations.

  • American City Business Journals5 hours ago

    Judge approves settlement between Allergan shareholders and Ackman

    Bill Ackman’s $290 million settlement agreement with shareholders of drug developer Allergan plc has the support of a California federal judge. This is good news for the New York-based activist investor and Valeant Pharmaceuticals, as the two parties are being sued for insider trading. “The Court has vacated the trial date and indicated its preliminary approval of the settlement subject to submission of final papers and associated hearings,” Valeant said in a statement.

  • The Wall Street Journal16 hours ago

    [$$] Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareholders and Pershing, Valeant

    A federal judge signaled he would approve a $290 million settlement reached by Pershing Square, Valeant and the shareholders of Allergan who had alleged the two firms improperly profited from their failed ...

  • InvestorPlaceyesterday

    Strong UnitedHealth Group Inc Earnings Keep Rally Going

    It’s exceedingly difficult to find something to dislike about UnitedHealth Group Inc (NYSE:UNH) stock. In a healthcare sector filled with minefields over the past few years, UnitedHealth stock has tripled over the past four years. Valuation might seem a slight concern, but UNH stock isn’t that expensive on an earnings basis, nor is its balance sheet particularly levered.

  • Barrons.comyesterday

    Getting Warmer? Valeant's Pipeline, Reduced Debt Make It Less Risky…But Not a Buy

    Shares of Valeant Pharmaceuticals International (VRX) have more than doubled the S&P 500's return during the past 12 months. H.C. Wainwright's Raghuram Selvaraju is warming to the stock. Valeant has made "significant strides" in moving its pipeline forward in recent months, he writes, while also making "substantial progress" on its debt.

  • What’s Teva Pharmaceutical’s Research and Development Strategy?
    Market Realistyesterday

    What’s Teva Pharmaceutical’s Research and Development Strategy?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.

  • Barrons.com5 days ago

    From Zit to Zip: Valeant Rises on Acne Drug Application

    Shares of Valeant Pharmaceuticals International (VRX) are higher on Friday, following acceptance of the application of one of its subsidiaries' acne medications. Valeant said that the Food and Drug Administration approved its New Drug Application for its tretinoin acne lotion, with an approval date of August 27, 2018.

  • CNW Group5 days ago

    Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

    Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

  • PR Newswire5 days ago

    Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form

    PDUFA Date Is Aug. 27, 2018 LAVAL, Quebec , Jan. 12, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") , ...

  • MarketWatch6 days ago

    Ackman’s Pershing Square cuts hedge-fund fees due to lawsuit settlement

    Pershing Square Holdings, the hedge fund operated by noted activist investor Bill Ackman, on Wednesday announced it was slashing its management fees, a move related to the settlement of two class-action ...

  • American City Business Journals6 days ago

    Bill Ackman slashes the annual management fee for Pershing Square hedge fund

    Activist investor Bill Ackman said he would slash the 1.5 percent annual management fee for his hedge fund Pershing Square Holdings Ltd. According to a letter posted to the Pershing Square (PSHZF) website, Ackman says he will be reducing future management fees for all of the funds which incurred recent litigation expenses by a total of $32.2 million. The litigation referenced in the letter pertains to Ackman and Valeant Pharmaceuticals' settling a long-standing dispute against drug developer Allergan plc.

  • Is Valeant Pharmaceuticals Intl Inc a Buy? 3 Pros, 3 Cons
    InvestorPlace6 days ago

    Is Valeant Pharmaceuticals Intl Inc a Buy? 3 Pros, 3 Cons

    Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has been on a tear in recent months, nearly doubling since November 1, when it closed at $11.93 a share. Valeant announced its results on November 7, with the news it beat analyst estimates for both revenue and net income. The company has also made progress in reducing its substantial debt burden.

  • Stocks can still go up, but volatility is back and here to stay: NYSE trader
    Yahoo Finance Video2 hours ago

    Stocks can still go up, but volatility is back and here to stay: NYSE trader

    Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest in the markets.

  • Spotlight on Valeant's Allergan settlement
    CNBC Videos21 hours ago

    Spotlight on Valeant's Allergan settlement

    Investors and Valeant's management likely want closure on the case, says Timothy Chiang of BTIG.